Table 4.
Cytokines polymorphism assessment
| Patients (n=80) | Controls (n=100) | |||||
|---|---|---|---|---|---|---|
| Position | Genotypes | No. | % | No. | % | |
| IL–1β | +3962 | TT | 7 | 8 | 4 | 4 |
| IL–1RA | mspa1 11100 | CC, CT | 3, 42 | 4, 53 | 17, 36 | 17, 36 |
| IL–12 | –1188 | CC | 10 | 12 | 2 | 2 |
| γ–IFN | +874 | AT | 54 | 68 | 39 | 39 |
| TGF–β1 | Codon 10 | TT | 29 | 36 | 13 | 13 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| IL–2 | –330 | GT | 43 | 54 | 34 | 34 |
| +166 | TT | 8 | 10 | 5 | 5 | |
| IL–4 | –1098 | GT | 24 | 30 | 21 | 21 |
| –33 | CT | 14 | 16 | 8 | 8 | |
| IL–10 | –1082 | GG | 10 | 12 | 6 | 6 |
| –592 | CC | 51 | 64 | 38 | 38 |